Commercial stage pharmaceutical company: Harmony Biosciences Holdings (HRMY) (2017 – )

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania, USA. It has 150 full-time employees. It is a commercial-stage pharmaceutical company dedicated to treating rare neurological diseases. And patients with unmet medical needs develop innovative therapies and commercialize them.

Harmony Biosciences

Harmony Biosciences Holdings (HRMY):

Harmony Biosciences is a pharmaceutical company founded in October 2017 with a vision to develop and commercialize novel treatment options for people with rare neurological diseases. Focusing on sleep disorders, Harmony Biosciences is currently working to improve the understanding of narcolepsy and to provide information and resources to people who coexist with it and to healthcare professionals who treat this chronic debilitating neurological disease.

Harmony Biosciences’ product WAKIX (stimulant) is a first-class molecule with a novel mechanism of action (MOA), specifically designed to enhance histamine signaling in the brain by binding to H3 receptors. In August 2019, WAKIX was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Excessive Daytime Sleepiness (EDS) in adult patients with narcolepsy (Narcolepsy). Began commercial use in the United States. WAKIX is the first and only approved product for narcolepsy patients, and it is not planned to be a controlled substance.

Harmony Biosciences Holdings (HRMY) financing:

  • On October 6, 2017 , in Series A financing, Harmony Biosciences received a joint investment of US$270 million from 7 institutions including HBM Healthcare Investments AG, Vivo Capital, Fidelity Management and Research Company, Valor Equity Partners, and venBio Partners.
  • On March 13, 2019, in Series B financing, Harmony Biosciences received an exclusive investment of US$200 million from CRG LP.
  • On August 26, 2019, Series C financing, Harmony Biosciences received US$50 million in investment.
  • On January 27, 2020, in Series D financing, Harmony Biosciences received an exclusive investment of US$200 million from OrbiMed.

Harmony Biosciences Holdings (HRMY) investment:

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) listed on NASDAQ on 8/19/2020 IPO, planned to issue price of $20.00-$23.00, actual issue price of US$24, issue 4.7 million shares, raise funds $112.8 million, underwritten by Goldman Sachs/ Jefferies/ Piper Sandler.

Notify of
Inline Feedbacks
View all Intels

Biopharmaceutical company: Oramed Pharmaceuticals Inc. (ORMP) (2002 – )

German clinical stage biopharmaceutical company: CureVac NV (CVAC) (2000 – )